Evidence map›Paper›PMID 41290673›Full record

ArticleNature communications2025

Bioorthogonal optimized virus immuno-nanomedicine (BOVIN).

Wenchang Peng, Yajing Du, Luna Cui, Yi Xiao, Lavonda Li, Lijie Yan, Yun Gu, Lulu Zhang, Bowen Li, Zhiyun Wang and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Machine-Learning Microfluidic Minute-Scale Microorganism Metrics Monitoring(M6).Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Wenchang Peng *School of Life Sciences, Tianjin University, Tianjin, China.ORCID http://orcid.org/0009-0009-4798-3212
Yajing Du *School of Life Sciences, Tianjin University, Tianjin, China.
Luna Cui *School of Life Sciences, Tianjin University, Tianjin, China.
Yi XiaoSchool of Engineering and Applied Sciences, Harvard University, Cambridge, MA, USA.
Lavonda LiWorld Tea Organization, Cambridge, MA, USA.ORCID http://orcid.org/0009-0003-9736-0570
Lijie YanWorld Tea Organization, Cambridge, MA, USA.ORCID http://orcid.org/0009-0000-4811-9252
Yun GuSchool of Life Sciences, Tianjin University, Tianjin, China.
Lulu ZhangSchool of Biomedical Engineering and Technology, Tianjin Medical University, Tianjin, China.
Bowen LiSchool of Biomedical Engineering and Technology, Tianjin Medical University, Tianjin, China.ORCID http://orcid.org/0009-0000-2712-1812
Zhiyun WangSchool of Environmental Science and Engineering, Tianjin University, Tianjin, China.
Hua WangSchool of Pharmaceutical Science and Technology, Tianjin University, Tianjin, China.
Xinyu DaiSchool of Life Sciences, Tianjin University, Tianjin, China.
Yue TengState Key Laboratory of Pathogen and Biosecurity Beijing Institute of Microbiology and Epidemiology, Beijing, China. yueteng@me.com.ORCID http://orcid.org/0000-0002-1566-9685
Tao WangSchool of Life Sciences, Tianjin University, Tianjin, China. wangtaobio@tju.edu.cn.ORCID http://orcid.org/0000-0003-1490-7407
Bin ZhengSchool of Biomedical Engineering and Technology, Tianjin Medical University, Tianjin, China. binzheng@tju.edu.cn.ORCID http://orcid.org/0000-0002-0369-5560
Xingcai ZhangWorld Tea Organization, Cambridge, MA, USA. drtea1@wteao.com.ORCID http://orcid.org/0000-0001-7114-1095

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The failure of tumour immunotherapy can be attributed to two primary factors: the limited immunogenicity of tumour cells and the immunosuppressive characteristics of the tumour microenvironment. Recent research indicates that cancer patients infected with respiratory viruses exhibit a positive antitumour response, as the activated host immune system. Here we show a bioorthogonal optimized virus immuno-nanomedicine (BOVIN) that uses nonpathogenic recombinant virus immuno-nanomedicine (VIN) for the targeted therapy of solid tumours. The influenza viruses (A/WSN/1933(WSN)) induce immunogenic cell death (ICD) in tumour cells by triggering a stress response mediated by integrated mitochondrial dysregulation. Furthermore, the surface modification of WSN with lactate oxidase enables the consumption of lactate to produce hydrogen peroxide, which synergistically enhance ICD activation. This leads to the attraction and significant activation of antigen-presenting cells in the tumour region through the exposure of calreticulin and secretion of high mobility group box 1. Additionally, the BOVIN triggers the tumour ICD, significantly enhances CD8

Indexed as

ImmunotherapyNanomedicineNeoplasmsAnimalsCD8-Positive T-LymphocytesCell Line, TumorFemaleHumansImmunogenic Cell DeathMiceMice, Inbred C57BLTumor Microenvironment

Identifiers

PMID41290673
PMCPMC12789605

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.